Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2022 | What to look forward to at ELCC 2022

Triparna Sen • 21 Mar 2022
ELCC 2022
Lung Cancer

Triparna Sen, PhD, MS, BS, Memorial Sloan Kettering Cancer Center, New York, NY, talks on what she’s looking forward to at the European Lung Cancer Congress 2022, including talks on therapeutic resistance and novel therapeutic strategies in lung cancer. However, given Dr Sen interests, she is most excited for discussions on immunotherapeutic approaches for lung cancer treatment. This interview took place during the virtual European Lung Cancer Congress 2022.

More from Triparna Sen

3:33
Molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer
Triparna Sen • 8 Aug 2022
2:11
Combination of WEE1 inhibition and immunotherapy provides promising preclinical data for SCLC
Triparna Sen • 21 Mar 2022
2:15
DNA damage repair pathways and WEE1 as possible therapeutic targets in SCLC
Triparna Sen • 21 Mar 2022
2:56
Current therapeutic landscape for small-cell lung cancer
Triparna Sen • 21 Mar 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals